A carregar...
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in un...
Na minha lista:
| Publicado no: | Ther Adv Respir Dis |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6831969/ https://ncbi.nlm.nih.gov/pubmed/31686616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466619885530 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|